Related Experiment Videos
Ventricular arrhythmias in dilated cardiomyopathy
J Brachmann1, T Hilbel, E Grünig
1Department of Cardiology, University Hospital, Heidelberg, Germany. johannesbrachmann@krzmail.krz.uni-heidelberg.de
Insights
Sudden cardiac death remains a risk in dilated cardiomyopathy (DCM) despite improved treatments. Current methods for predicting risk are limited, but implantable cardioverter-defibrillators (ICDs) show promise for managing arrhythmias.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Research
Background:
- Dilated cardiomyopathy (DCM) prognosis has improved, yet sudden cardiac death (SCD) remains a significant concern.
- Spontaneous ventricular ectopy is common in DCM, but its prognostic value via Holter monitoring is debated.
- Noninvasive methods like late potentials and QT dispersion lack established prognostic utility for arrhythmogenic events in DCM.
Purpose of the Study:
- To review the current prognostic strategies for sudden cardiac death in dilated cardiomyopathy.
- To evaluate the effectiveness of various diagnostic and therapeutic interventions in predicting and preventing adverse outcomes in DCM patients.
- To explore emerging treatments for advanced DCM with high arrhythmia risk.
Main Methods:
- Review of existing literature on prognostic markers in dilated cardiomyopathy.
- Analysis of data regarding Holter monitoring, late potentials, QT dispersion, and programmed ventricular stimulation.
- Evaluation of preliminary data on implantable cardioverter-defibrillators (ICDs) and their role in risk stratification.
- Consideration of advanced therapies including heart transplantation and dynamic cardiomyoplasty.
Main Results:
- The prognostic significance of Holter monitoring for ventricular ectopy in DCM is controversial.
- Programmed ventricular stimulation has not consistently identified patients at risk for sudden death.
- Preliminary data suggest implantable cardioverter-defibrillators (ICDs) are promising for risk stratification in DCM.
- Progression of heart failure dictates prognosis in DCM patients with poor left ventricular function and ICDs.
Conclusions:
- Despite advances, sudden cardiac death remains a challenge in dilated cardiomyopathy.
- Current noninvasive and electrophysiological testing methods have limitations in predicting prognosis.
- Implantable cardioverter-defibrillators (ICDs) appear promising for managing arrhythmia risk in DCM.
- For end-stage heart failure, heart transplantation is definitive, while ICDs combined with dynamic cardiomyoplasty offer an alternative for high-risk, non-transplant candidates.
Abstract:
Although prognosis of dilated cardiomyopathy (DCM) has improved due to advances in diagnosis and therapy, still too many sudden cardiac deaths occur in DCM. Spontaneous ventricular ectopy is a very common finding in patients with DCM, but the prognostic significance of Holter monitoring remains controversial. Other noninvasive methods, e.g., late potentials and QT dispersion, have not yet contributed to the evaluation of prognosis for arrhythmogenic events in DCM. Programmed ventricular stimulation has been repeatedly used to stratify long-term prognosis, yet satisfactory data are still missing as many deaths occur in patients without inducible arrhythmias. Several prognostic studies are still in progress, and preliminary data for the use of ICDs already appear to be promising. In patients with poor left ventricular function and ICDs in situ, prognosis is determined by progression of heart failure. Heart transplantation may be the ultimate therapeutic instrument for end-stage heart failure patients. For patients with advanced DCM and increased risk for malignant arrhythmias who are unsuitable for orthotopic heart transplantation, the combined therapy with an ICD and dynamic cardiomyoplasty may be an alternative treatment.